Table 1.
Baseline Characteristics by Baseline BLR and Baseline Basophils at Optimal Cut.
| Baseline Basophils at optimal cutΨ | Baseline BLR at optimal cut Ω | ||||||
|---|---|---|---|---|---|---|---|
| Variable | Level | Below N=68 | Above N=97 | p-value* | Below N=141 | Above N=24 | p-value* |
| Drug under investigation | Docetaxel | 76 (53.90) | 16 (66.67) | 0.244 | 38 (55.88) | 54 (55.67) | 0.978 |
| Abiraterone | 65 (46.10) | 8 (33.33) | 30 (44.12) | 43 (44.33) | |||
| Race | Black | 68 (48.23) | 21 (87.50) | <0.001 | 51 (75.00) | 38 (39.18) | <0.001 |
| Non-Black | 73 (51.77) | 3 (12.50) | 17 (25.00) | 59 (60.82) | |||
| Age at diagnosis | <65 | 73 (51.77) | 16 (66.67) | 0.176 | 40 (58.82) | 49 (50.52) | 0.292 |
| >=65 | 68 (48.23) | 8 (33.33) | 28 (41.18) | 48 (49.48) | |||
| PSA at diagnosis at | Above | 73 (52.9) | 18 (75) | 0.044 | 44 (64.71) | 47 (50) | 0.063 |
| optimal cut 37.2 (ng/mL) | Below | 65 (47.1) | 6 (25) | 24 (35.29) | 47 (50) | ||
| Total Gleason score | 7 | 22 (15.60) | 1 (4.17) | 0.282 | 10 (14.71) | 13 (13.4) | 0.743 |
| 8–10 | 89 (63.12) | 16 (66.67) | 41 (60.29) | 64 (65.98) | |||
| Unknown | 30 (21.28) | 7 (29.17) | 17 (25.00) | 20 (20.62) | |||
| ECOG at time of starting treatment a | 0 | 71 (50.35) | 4 (16.67) | 0.002 | 29 (42.65) | 46 (47.42) | 0.829 |
| 1 | 53 (37.59) | 12 (50.00) | 28 (41.18) | 37 (38.14) | |||
| 2 | 17 (12.06) | 8 (33.33) | 11 (16.18) | 14 (14.43) | |||
| Number of distant metastases b | 0–1 | 41 (29.08) | 3 (12.50) | 0.090 | 20 (29.41) | 24 (24.74) | 0.504 |
| 2–4+ | 100 (70.92) | 21 (87.50) | 48 (70.59) | 73 (75.26) | |||
| Disease volume c | High | 90 (63.83) | 18 (78.26) | 0.176 | 50 (73.53) | 58 (60.42) | 0.081 |
| Low | 51 (36.17) | 5 (21.74) | 18 (26.47) | 38 (39.58) | |||
a
Eastern Cooperative Oncology Group (ECOG) performance status, ranging from 0 to 5, with lower scores indicating better functionality.
b
Number of anatomical locations (lymph nodes = 1, bone = 1, liver = 1, lung = 1, brain = 1)
c
Disease volume is classified as high-volume disease based on CHAARTED criteria of visceral metastases or ≥ 4 bone lesions with ≥1 beyond axial skeleton
*
The p-value is calculated by Chi-square test or Fisher’s exact test, wherever appropriate.
Ψ
“Below” defined as <0.1. “Above” defined as ≥0.1, with 0.1 being optimal cut.
Ω
“Below” defined as <0.0142, “Above” defined as ≥ 0.0142, with 0.0142 being optimal cut